Lenrispodun (also known as ITI-214) is being evaluated as an adjunctive therapy for Parkinson's disease patients experiencing motor fluctuations. This Phase 2 trial is sponsored by Intra-Cellular Therapies, Inc.[1].
Lenrispodun is an investigational drug developed by Intra-Cellular Therapies, Inc. as an adjunctive therapy for Parkinson's disease patients experiencing motor fluctuations. The drug completed a Phase 2 clinical trial (NCT05766813) evaluating its efficacy and safety in patients with levodopa-induced dyskinesia and wearing-off symptoms.
Intra-Cellular Therapies is a pharmaceutical company known for developing central nervous system therapies, including the FDA-approved drug cariprazine (Vraylar) for schizophrenia and bipolar disorder. Their pipeline includes several phosphodiesterase inhibitors targeting various CNS disorders.
| Field | Details |
|---|---|
| NCT Number | NCT05766813 |
| Phase | Phase 2 |
| Status | Recruiting |
| Start Date | March 13, 2023 |
| Primary Completion | September 2025 (Estimated) |
| Study Completion | October 2025 (Estimated) |
| Sponsor | Intra-Cellular Therapies, Inc. |
| Enrollment | 132 patients (estimated) |
The trial was designed as a multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study:
While the specific mechanism of action for lenrispodun has not been fully disclosed in public literature, the drug is being developed within Intra-Cellular Therapies' phosphodiesterase inhibitor pipeline. Based on the company's research focus and the trial's target indication (motor fluctuations and dyskinesia), the mechanism likely involves:
The basal ganglia motor circuit relies heavily on proper cAMP signaling for regulating movement. Phosphodiesterase inhibitors can modulate this pathway, potentially reducing the dysregulated signaling that leads to dyskinesia.
Motor fluctuations (wearing-off phenomenon) are a common complication of long-term levodopa therapy in Parkinson's disease. As the disease progresses, patients experience decreasing duration of benefit from each levodopa dose, leading to predictable ON/OFF cycles.
Current treatments for motor fluctuations include:
There remains a significant need for novel agents that can reduce dyskinesia without compromising motor control.
Lenrispodun represents a novel approach to managing these fluctuations through its mechanism (likely dopamine-related modulation), potentially offering improved symptom control when added to standard levodopa therapy.
Intra-Cellular Therapies has been developing multiple CNS drugs targeting phosphodiesterases. Their pipeline approach focuses on: